Bristol-Myers Squibb Company
NYSE: BMY
$49.38
+$0.36 (+0.7%)
Closing Price on September 20, 2024
BMY Articles
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
Published:
Last Updated:
Fourth-quarter and full-year earnings at Bristol-Myers Squibb beat estimates, but a report of the successful trial of the company's lung cancer treatment may be the big mover for the stock Monday.
Published:
Last Updated:
24/7 Wall St. has put together a preview of Disney, General Motors, Twitter and other major companies scheduled to report their quarterly results this week.
Published:
Last Updated:
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5% correction, it may make sense to move to some safer higher ground.
Published:
Last Updated:
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
Published:
Last Updated:
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
Published:
Last Updated:
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Published:
Last Updated:
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Published:
Last Updated:
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
Published:
The October 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
Published:
Last Updated: